Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Ophthalmol. 2005 Oct;89(10):1363-7.

Topical ciclosporin in the treatment of ocular surface disorders.

Author information

1
The Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, MD 21287-9238, USA.

Abstract

Mounting evidence suggests that inflammation is the key factor in the pathogenesis of various ocular surface diseases, with a complex interplay of genetic, environmental, and psychosocial factors. Management of these conditions is often challenging. Topical corticosteroids, with their associated side effects, are the mainstay of current treatments for patients with vision threatening disease. Ciclosporin A is an immunomodulator that specifically inhibits T lymphocyte proliferation. Recently, a topical ciclosporin preparation was approved by the US Food and Drug Administration and became available for use in ophthalmology. Given the increasing use of ciclosporin eye drops, the goal of this article is to provide the reader with an overview of the well established uses of ciclosporin and to help refine the questions that should be addressed by future investigations.

PMID:
16170133
PMCID:
PMC1772855
DOI:
10.1136/bjo.2005.070888
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center